• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BD Expands PureWick™ Portfolio with First-of-its-Kind Portable Solution to Confidently Manage Urinary Incontinence On the Go

    11/12/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email

    FRANKLIN LAKES, N.J., Nov. 12, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, introduces the PureWick™ Portable Collection System, a discreet, first-of-its-kind, battery-powered personal urine management device designed for wheelchair users to help improve mobility around and outside the home.

    BD Expands PureWick™ Portfolio with First-of-its-Kind Portable Solution to Confidently Manage Urinary Incontinence On the Go

    The PureWick™ Portable Collection System builds on the success of the PureWick™ Urine Collection System, the #1 external catheter used in hospitals. The non-invasive device uses gentle suction technology that draws voided urine away from the body through tubing that is connected to a collection canister for easy disposal and can be placed beside a bed or chair, or mounted on a wheelchair.

    "Urinary incontinence is a common yet under-discussed condition that impacts 25 million Americans and can have profound effects on confidence, social engagement and quality of life, especially among those with mobility challenges," said Mike Cusack, worldwide president of Urology and Critical Care at BD. "With the launch of the PureWick™ Portable Collection System, we have an opportunity to help people regain their confidence and independence by delivering a discreet, accessible solution that empowers individuals to participate more fully in everyday activities."

    Freedom, Comfort, and Confidence – Wherever You Go

    • Comfort and discretion – The non-invasive collection system works outside the body and has a quiet operation and simple setup for use at home or on the go; a discreet Carry Bag conceals the system
    • Freedom of movement – The portable power and lightweight design allow it to be placed beside a bed or chair, carried, or mounted on a wheelchair with a battery life of up to eight hours
    • Confidence and independence – Empowers men and women and their caregivers managing urinary incontinence to maintain their active lifestyle and dignity
    • Reduced risk for skin irritation – Helps reduce the risk of one of the leading causes of skin damage by drawing voided urine away from the body.

    An Innovative Evolution of a Trusted Solution

    To date, more than 55 million PureWick™ External Catheters have been sold, and over 4,500 hospitals and rehabilitation facilities across the U.S. rely on this technology. In a survey that included 150 users and caregivers, more than 90% would recommend the PureWick™ Urine Collection System, underscoring its impact and trust among caregivers and patients alike. The PureWick™ Portable Collection System is compatible with both the PureWick™ Flex Female External Catheter and PureWick™ Male External Catheter.

    "For years, the BD PureWick™ Urine Collection System has expanded the options for people managing urinary incontinence," said Cusack. "With this latest innovation in our PureWick™ portfolio we're expanding that same trusted technology beyond the bedside - empowering users with urinary incontinence to now live their daily lives with freedom and peace of mind at home or on the go."

    The PureWick Portable Collection System is available at PureWickAtHome.com or by calling 1-800-323-0914.

    About BD

    BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiency, improve safety, and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

    Contacts:







    Media:                                                                                                                 

    Investors:

    Fallon McLoughlin                                                                                            

    Adam Reiffe

    Director, Public Relations                                                                              

    VP, Investor Relations

    201.258.0361                                                                                                      

    201.847.6927

    [email protected]                                                                          

    [email protected]                     

     

    BD (Becton, Dickinson and Company) Logo (PRNewsfoto/BD (Becton, Dickinson and Company))

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-expands-purewick-portfolio-with-first-of-its-kind-portable-solution-to-confidently-manage-urinary-incontinence-on-the-go-302612350.html

    SOURCE BD (Becton, Dickinson and Company)

    Get the next $BDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    5/2/2025Outperform → Mkt Perform
    Raymond James
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    5/1/2025$190.00Buy → Neutral
    BofA Securities
    5/1/2025Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scott Bertram L sold $38,318 worth of shares (217 units at $176.58), decreasing direct ownership by 0.60% to 35,816 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    11/7/25 5:36:46 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Byington Carrie L

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    11/4/25 8:41:02 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Jones Christopher Ian Montague

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    11/4/25 8:36:53 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/10/25 5:03:18 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Becton Dickinson with a new price target

    RBC Capital Mkts initiated coverage of Becton Dickinson with a rating of Sector Perform and set a new price target of $211.00

    9/25/25 8:27:46 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson downgraded by Citigroup with a new price target

    Citigroup downgraded Becton Dickinson from Buy to Neutral and set a new price target of $185.00

    5/22/25 8:18:13 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Becton Dickinson from Overweight to Neutral and set a new price target of $185.00

    5/2/25 8:06:47 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BD Expands PureWick™ Portfolio with First-of-its-Kind Portable Solution to Confidently Manage Urinary Incontinence On the Go

    FRANKLIN LAKES, N.J., Nov. 12, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, introduces the PureWick™ Portable Collection System, a discreet, first-of-its-kind, battery-powered personal urine management device designed for wheelchair users to help improve mobility around and outside the home. The PureWick™ Portable Collection System builds on the success of the PureWick™ Urine Collection System, the #1 external catheter used in hospitals. The non-invasive device uses gentle suction technology that draws voided 

    11/12/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

    Q4 revenue of $5.9 billion increased 8.3% as reported, 7.0% FXN and 3.9% organicQ4 GAAP and adjusted diluted EPS grew to $1.72 and $3.96, respectivelyFY25 revenue of $21.8 billion increased 8.2% as reported, 7.7% adjusted FXN and 2.9% organicFY25 GAAP EPS of $5.82 decreased 0.7%; adjusted diluted EPS of $14.40 grew 9.6%FY25 GAAP and adjusted gross margin up 20 basis points and 140 basis points, respectively, driven by BD ExcellenceFY25 GAAP operating margin down 10 basis points to 11.8%; adjusted operating margin up 80 basis points to 25.0%Returned $2.2 billion to shareholders in FY25 through dividends and share repurchasesCompany issues FY26 guidanceFRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNew

    11/6/25 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Board Increases Dividend for 54th Consecutive Year

    FRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of $1.05 per common share, an increase of 1.0% from the previous quarter. The dividend will be payable on December 31, 2025 to holders of record on December 8, 2025. The indicated annual dividend rate for fiscal year 2026 is $4.20 per share. "This is the 54th consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years," said Tom Polen, chairman, CEO and president of BD. "This inc

    11/6/25 6:25:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Financials

    Live finance-specific insights

    View All

    BD Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

    Q4 revenue of $5.9 billion increased 8.3% as reported, 7.0% FXN and 3.9% organicQ4 GAAP and adjusted diluted EPS grew to $1.72 and $3.96, respectivelyFY25 revenue of $21.8 billion increased 8.2% as reported, 7.7% adjusted FXN and 2.9% organicFY25 GAAP EPS of $5.82 decreased 0.7%; adjusted diluted EPS of $14.40 grew 9.6%FY25 GAAP and adjusted gross margin up 20 basis points and 140 basis points, respectively, driven by BD ExcellenceFY25 GAAP operating margin down 10 basis points to 11.8%; adjusted operating margin up 80 basis points to 25.0%Returned $2.2 billion to shareholders in FY25 through dividends and share repurchasesCompany issues FY26 guidanceFRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNew

    11/6/25 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Board Increases Dividend for 54th Consecutive Year

    FRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of $1.05 per common share, an increase of 1.0% from the previous quarter. The dividend will be payable on December 31, 2025 to holders of record on December 8, 2025. The indicated annual dividend rate for fiscal year 2026 is $4.20 per share. "This is the 54th consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years," said Tom Polen, chairman, CEO and president of BD. "This inc

    11/6/25 6:25:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Announces CFO Transition Plan

    Provides Preliminary Revenue for Fourth Quarter and Full Year Fiscal 2025  FRANKLIN LAKES, N.J., Oct. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today a transition plan under which Chris DelOrefice, executive vice president and chief financial officer (CFO), will depart the company effective Dec. 5, 2025, to pursue a new professional opportunity. The company is conducting a search to identify a permanent successor. Vitor Roque, senior vice president of finance, business units and corporate financial planning and analysis, has been named interim CFO and will assume the role effective upon DelOrefice's departur

    10/15/25 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/16/24 4:29:42 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/14/24 10:02:59 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/13/24 5:00:53 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    SEC Filings

    View All

    Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    11/6/25 6:32:28 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    10/15/25 4:18:58 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    9/17/25 8:46:05 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Leadership Updates

    Live Leadership Updates

    View All

    BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative

    FRANKLIN LAKES, N.J., Sept. 2, 2025 /PRNewswire/ -- In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE:BDX) is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts blood flow to the limbs and is a leading cause of preventable amputations. https://loveyourlimbs.com to learn more or get involved." alt="September is Peripheral Artery Disease Awareness Month. Visit https://loveyourlimbs.com to learn more or get involved."> PAD affects more than 21 million Americans1 and more than 200 milli

    9/2/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment

    FRANKLIN LAKES, N.J., July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin has been named executive vice president and will become the president of BD's future Connected Care segment, as part of the company's previously announced plans to update its structure as it advances its New BD strategy. Mushin will serve as a member of the BD Executive Leadership Team reporting to Tom Polen, chairman, CEO and president of BD and will lead the strategy development to support an effective transition into this new structure over the next several months.

    7/7/25 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Names Gregory J. Hayes to Board of Directors

    FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive experience, having held chief executive officer and senior leadership roles across finance, corporate strategy and business development f

    3/27/25 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care